
Mirabegron (50mg) + Solifenacin (5mg)
Active composition
+1 more active ingredient
Solifenacin antagonizes muscarinic receptors in the bladder, reducing detrusor muscle contractions and increasing bladder capacity.
Medical applications
Mirahype S 50/5 Tablet ER is a once-daily, extended-release formulation containing mirabegron (50mg) and solifenacin (5mg), a combination therapy for the treatment of overactive bladder (OAB) with symptoms of urinary frequency, urgency, and incontinence. This product is designed to provide sustained release of its active ingredients, mirabegron and solifenacin, over an extended period, allowing for consistent and reliable therapeutic effects. Mirabegron, a β3-adrenoceptor agonist, increases urinary bladder capacity and reduces urgency, while solifenacin, a muscarinic receptor antagonist, reduces the frequency of bladder contractions and urinary incontinence episodes. The combination of these two compounds synergistically works together to provide enhanced relief from OAB symptoms. Mirahype S 50/5 Tablet ER is indicated for patients who have not responded adequately to previous therapy or who have intolerable side effects. This product is contraindicated in patients with known hypersensitivity to either mirabegron or solifenacin, and caution should be exercised in patients with moderate to severe renal impairment.
Dosage information not available. Please consult your doctor or pharmacist.
Important precautions
Based on clinical trials and patient reports.
Overall Tolerance
Common Side Effects
Information regarding the use of Mirahype S 50/5 Tablet ER during pregnancy is not available. Please consult your doctor.
High Risk
Information regarding the use of Mirahype S 50/5 Tablet ER during breastfeeding is not available. Please consult your doctor.
Medical Advice
There is limited information available on the use of Mirahype S 50/5 Tablet ER in patients with kidney disease. Please consult your doctor.
Exercise Caution
It is not known whether Mirahype S 50/5 Tablet ER alters the ability to drive. Do not drive if you experience any symptoms that affect your ability to concentrate and react.
Consult Doctor
There is limited information available on the use of Mirahype S 50/5 Tablet ER in patients with liver disease. Please consult your doctor.
Regular Checkup
0 reviews for Mirahype S 50/5 Tablet ER

Mirabegron (50mg) + Solifenacin (5mg)
Cheaper alternative availability
This medicine doesn't have a cheaper alternative with the same composition. Our health advisors can help you find other savings options based on your prescription.
Active composition
+1 more active ingredient
Solifenacin antagonizes muscarinic receptors in the bladder, reducing detrusor muscle contractions and increasing bladder capacity.
Medical applications
Mirahype S 50/5 Tablet ER is a once-daily, extended-release formulation containing mirabegron (50mg) and solifenacin (5mg), a combination therapy for the treatment of overactive bladder (OAB) with symptoms of urinary frequency, urgency, and incontinence. This product is designed to provide sustained release of its active ingredients, mirabegron and solifenacin, over an extended period, allowing for consistent and reliable therapeutic effects. Mirabegron, a β3-adrenoceptor agonist, increases urinary bladder capacity and reduces urgency, while solifenacin, a muscarinic receptor antagonist, reduces the frequency of bladder contractions and urinary incontinence episodes. The combination of these two compounds synergistically works together to provide enhanced relief from OAB symptoms. Mirahype S 50/5 Tablet ER is indicated for patients who have not responded adequately to previous therapy or who have intolerable side effects. This product is contraindicated in patients with known hypersensitivity to either mirabegron or solifenacin, and caution should be exercised in patients with moderate to severe renal impairment.
Dosage information not available. Please consult your doctor or pharmacist.
Important precautions
Based on clinical trials and patient reports.
Overall Tolerance
Common Side Effects
Information regarding the use of Mirahype S 50/5 Tablet ER during pregnancy is not available. Please consult your doctor.
High Risk
Information regarding the use of Mirahype S 50/5 Tablet ER during breastfeeding is not available. Please consult your doctor.
Medical Advice
There is limited information available on the use of Mirahype S 50/5 Tablet ER in patients with kidney disease. Please consult your doctor.
Exercise Caution
It is not known whether Mirahype S 50/5 Tablet ER alters the ability to drive. Do not drive if you experience any symptoms that affect your ability to concentrate and react.
Consult Doctor
There is limited information available on the use of Mirahype S 50/5 Tablet ER in patients with liver disease. Please consult your doctor.
Regular Checkup
0 reviews for Mirahype S 50/5 Tablet ER















